Expression of 14-3-3γ in patients with breast cancer: Correlation with clinicopathological features and prognosis

Cancer Epidemiology

Volumn 36, Issue 6, 2012, Pages 533-536

  Song, Yulan ^b   Yang, Zheng ^c   Ke, Zunfu ^c   Yao, Yunhong ^a   Hu, Xinrong ^a   Sun, Yanqin ^a   Li, Hongmei ^a   Yin, Jinbao ^a   Zeng, Chao ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

14 3 3 ; Breast cancer; Immunohistochemistry; Prognosis

Indexed keywords

PROTEIN 14 3 3; PROTEIN 14 3 3 GAMMA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

14-3-3 PROTEINS; ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868304430     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.05.003     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2007, 57:43-66.
2. Press M.F., Pike M.C., Chazin V.R., Hung G., Udove J.A., Markowicz M., et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression within creased risk of recurrent disease. Cancer Res 1993, 53:4960-4970.
3. Dougherty M.K., Morrison D.K. Unlocking the code of 14-3-3. J Cell Sci 2004, 117:1875-1884.
4. Aitken A., Collinge D.B., van Heusden B.P., Isobe T., Roseboom P.H., Rosenfeld G., et al. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci 1992, 17:498-501.
5. Mackintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulated inverse cellular processes. Biochem J 2004, 381:329-342.
6. Aitken A. 14-3-3 proteins a historic overview. Semin Cancer Biol 2006, 16:162-172.
7. Neal C.L., Yao J., Yang W.T. 14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009, 69:3425-3432.
8. Iwata N., Yamamoto H., Sasaki S., Itoh F., Suzuki H., Kikuchi T., et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000, 19:5298-5302.
9. Nacht M., Ferguson A.T., Zhang W., Petroziello J.M., Cook B.P., Gao Y.H., et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999, 59:5464-5470.
10. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Yu C.Y., et al. Identification of human hepatoceullular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005, 4:2062-2069.
11. Qi W., Liu X., Chen W., Li Q., Martinez J.D. Overexpression of 14-3-3γ causes polyploidization in H322 lung cancer cells. Mol Carcinogenesis 2007, 46:847-856.
12. Innocenzi D., Alo P.L., Balzani A., Sebastiani V., Silipo V., LaTorre G., et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 2003, 130:23-28.
13. Lodygin D., Diebold J., Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3σ expression. Oncogene 2004, 23:9034-9041.
14. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., Imai K. Inactivation of the 14-3-3σ gene is associated with 5'CpG island hypermethylation in human cancers. Cancer Res 2000, 60:4353-4357.
15. Yi B., Tan S.X., Tang C.E., Huang W.G., Cheng A.L., Li C., et al. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem 2009, 106:858-866.
16. INK4a silencing and human papilloma virus negativity. Cancer Res 2002, 62:2072-2076.
17. Kobayashi R., Deavers M., Patenia R., Rice-Stitt T., Halbe J., Gallardo S., et al. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunol Immunother 2009, 58:247-258.
18. Wu K.K., Liou J.Y. Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPAR delta 14-3-3 epsilon pathway. Methods Mol Biol 2009, 512:295-297.
19. Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., et al. Sirt2 interacts with 14-3-3beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 2008, 368:690-695.
20. Ajjappala B.S., Kim Y.S., Kim M.S., Lee M.Y., Lee K.Y., Ki H.Y., et al. 14-3-3γ is stimulated by IL-3 and promotes cell proliferation. J Immunol 2009, 182:1050-1060.
21. Jin Y., Dai M.S., Lu S.Z., Xu Y., Luo Z., Zhao Y., et al. 14-3-3γ binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J 2006, 25:1207-1218.
22. Radhakrishnan V.M., Martinez J.D. 14-3-3γ induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One 2010, 5:1-10.